Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06304103
Other study ID # AND017-MDS-206
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date December 2024
Est. completion date May 2027

Study information

Verified date March 2024
Source Kind Pharmaceuticals LLC
Contact Yusha Zhu, MD, PhD
Phone 6467252552
Email yushazhu@kindpharmaceutical.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2, multicenter, randomized, open-lable study to evaluate the efficacy and safety of luspatercept (ACE-536) for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS)in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 63
Est. completion date May 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Diagnosed of primary myelodysplastic syndrome with a PISS-R grading of very low, low or intermediate risk and a bone marrow primitive cell count < 5%, the time frame for this grading assessment should be at least 12 weeks prior to the first dose 2. Non-5q(del)-associated myelodysplastic syndrome. 3. Two non-transfused hemoglobin = 6.0 g/dL and < 10.0 g/dL, averaged over the screening period, at least one week and more apart, and with no more than 1.3 g/dL difference between the two Hb. 4. Non-transfused subjects (NTD cohort) defined as no red blood cell transfusion in the 16 weeks prior to randomization or low transfusion load subjects defined as 3-7 pRBC units transfused in the 16 weeks prior to randomization and at least two different time points (LTB-1 cohort) or 1-2 pRBC units transfused at one time point in the 16 weeks prior to randomization ( LTB-2 cohort) (except in the case of transfusion for treatment of other comorbidities such as blood loss, surgery, etc.); 5. Baseline EPO level = 500 mU/mL 6. Platelets = 30,000 /mm3 and absolute neutrophil count = 800/mm3 7. Adequate liver function with: - Total bilirubin <2 x upper limit of normal (ULN) (subjects with Gilbert's syndrome, i.e., unconjugated hyperbilirubinemia, have a total bilirubin <3 x ULN) - Aspartate aminotransferase (AST) <3 x ULN - Alanine aminotransferase (ALT) <3×ULN Exclusion Criteria: 1. Diagnosed of secondary myelodysplastic syndrome or concurrent anemia from a cause other than the primary myelodysplastic syndrome. 2. Significant myelofibrosis (fibrosis = 2+). 3. Planned clearing chemotherapy or whole brain spinal cord radiotherapy during the study period. 4. Previous diagnosis of MDS IPSS-R high or very high risk. 5. Prior or planned hematopoietic stem cell transplant during the study period. 6. Received granulocyte colony-stimulating factor (G-CSF), or thrombopoietin, or thrombopoietin receptor agonist therapy within 8 weeks prior to the first dose; 7. Treatment with antithymocyte globulin, azacitidine, decitabine, cyclosporine, thalidomide, or lenalidomide within 12 weeks prior to the first dose. 8. The presence of active infection or inflammatory disease requiring systemic anti-infective therapy, including concomitant autoimmune disease with inflammatory symptoms (e.g., generalized erythema, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, dry syndrome, celiac disease, etc.) 9. Concurrent retinal neovascularization requiring treatment (diabetic proliferative retinopathy, age-related exudative macular degeneration, retinal vein occlusion, macular edema, etc.) 10. Inability to take oral medications, or a history of gastrectomy, concomitant gastroparesis, or other conditions that may have an impact on the absorption of gastrointestinal medications (excluding gastric polyps or colonic polypectomy) 11. Clinically significant bleeding (including transfusions required to treat bleeding or bleeding resulting in a decrease in hemoglobin = 2 g/dL) within 4 weeks prior to the first dose, or a bleeding constitutional or bleeding risk that has not been medically or surgically corrected. 12. Uncontrolled hypertension (more than one-third of identifiable diastolic blood pressure values = 100 mmHg and/or systolic blood pressure = 160 mmHg at 16 weeks prior to and including screening testing) 13. Comorbid heart failure (New York Heart Association [NYHA] class III or higher) 14. Medical history of significant liver disease or active liver disease at screening assessment 15. Have been treated with any other hypoxia-inducing factor-prolyl hydroxylase inhibitor (HIF-PHI) in the 8 weeks prior to the first dose 16. Have been treated with an erythropoietic ESA within 8 weeks prior to the first dose 17. Have been treated with an androgenic anabolic steroid, testosterone enanthate or methandrostenolone within 8 weeks prior to the first dose 18. Have been treated with an iron chelator within 8 weeks prior to the first dose

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AND017
Administer AND017 once per day (QD)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Kind Pharmaceuticals LLC

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of HI-E/RBC-TI responding subjects NTD cohort: non-transfused Hb levels =1.5 g/dL relative to baseline* during any 8-week period from baseline to 24 weeks post-dose.
LTB-1 cohort: No transfusion during any 8-week period from baseline to 24 weeks post-dose.
LTB-2 cohort: No transfusions during any 8-week period from baseline to 24 weeks post-dose and untransfused Hb levels =1.5 g/dL.
Hb baseline is the average of the two lowest Hb over the 16 weeks prior to the first dose
From baseline to up to Week 25
Secondary Mean level and change from baseline in untransfused Hb throughout the first 8 weeks of treatment Mean level and change from baseline in untransfused Hb throughout the first 8 weeks of treatment Baseline, Week 3, 5, 7, and 9
Secondary Mean level and change from baseline in untransfused Hb at each visit throughout the treatment period and Mean level and change from baseline in untransfused Hb at each visit throughout the treatment period and Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Secondary Percentage of visits in which untransfused Hb was maintained in this range after reaching two consecutive increases of =1.5 g/dL and =1.0 g/dL from baseline, respectively, throughout the treatment period Percentage of visits in which untransfused Hb was maintained in this range after reaching two consecutive increases of =1.5 g/dL and =1.0 g/dL from baseline, respectively, throughout the treatment period Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Secondary Mean time required after two consecutive increases in untransfused Hb =1.5 g/dL and =1.0 g/dL from baseline, respectively, throughout the treatment period Mean time required after two consecutive increases in untransfused Hb =1.5 g/dL and =1.0 g/dL from baseline, respectively, throughout the treatment period Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Secondary For changes in mean transfusion units throughout the treatment period compared to baseline (mean transfusion units 16 weeks prior to first dose) For changes in mean transfusion units throughout the treatment period compared to baseline (mean transfusion units 16 weeks prior to first dose) Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Secondary For LTB cohorts, the average time required to reach first transfusion independence throughout the treatment period For LTB cohorts, the average time required to reach first transfusion independence throughout the treatment period Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Secondary Levels of reticulocyte count at each visit and change from baseline Levels of reticulocyte count at each visit and change from baseline Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Secondary Levels of hematocrit at each visit and change from baseline Levels of hematocrit at each visit and change from baseline Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Secondary Levels of mean corpuscular volume at each visit and change from baseline Levels of mean corpuscular volume at each visit and change from baseline Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
Secondary Levels of mean corpuscular hemoglobin at each visit and change from baseline Levels of mean corpuscular hemoglobin at each visit and change from baseline Baseline, Week 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Terminated NCT04313881 - Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) Phase 3
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Recruiting NCT04701229 - Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
Suspended NCT04485065 - Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS Phase 1
Recruiting NCT04174547 - An European Platform for Translational Research in Myelodysplastic Syndromes
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Completed NCT02508870 - A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Phase 1
Completed NCT04543305 - A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Recruiting NCT05365035 - A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts Phase 2
Recruiting NCT06008405 - Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1